Evidence map›Paper›PMID 37293032›Full record

ArticlebioRxiv : the preprint server for biology2023

Pathological Tau transmission initiated by binding lymphocyte-activation gene 3.

Chan Chen, Ramhari Kumbhar, Hu Wang, Xiuli Yang, Kundlik Gadhave, Cyrus Rastegar, Yasuyoshi Kimura, Adam Behensky, Sruthi Katakam, Deok Jeong and 15 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 1 country.

Chan ChenNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Ramhari KumbharNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Hu WangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Xiuli YangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kundlik GadhaveNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Cyrus RastegarNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Yasuyoshi KimuraNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Adam BehenskyNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Sruthi KatakamNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Deok JeongNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Liang WangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Anthony WangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Rong ChenNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Shu ZhangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Lingtao JinDepartment of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Creg J WorkmanDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Dario A A VignaliDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Olga PletinkovaDepartment of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
David W NauenDepartment of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Philip C WongDepartment of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Juan C TroncosoDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Mingyao YingDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Valina L DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Ted M DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Xiaobo MaoNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Johns Hopkins University · USUniversity of Pittsburgh · USKennedy Krieger Institute · USThe University of Texas Health Science Center at San Antonio · US

Funding

Project 2 MeasurementU19AG033655 · NIA · JOHNS HOPKINS UNIVERSITY · PI Mei Cheng Wang · 2014 to 2026
$51.5M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI ALBERT, MARILYN S. · 1985 to 2019
$37.6M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
Biomarkers of Cognitive Decline among Normal Individuals: The BIOCARD cohortU01AG033655 · NIA · JOHNS HOPKINS UNIVERSITY · PI ALBERT, MARILYN S. · 2009 to 2013
$11.2M
Murine Mutagenesis CoreP30NS050274 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOLODKIN, ALEX L · 2005 to 2020
$10.9M
Structure, Function and Mechanistic Analysis of LAG3R01AI144422 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Roy A Mariuzza, Dario AA Vignali · 2019 to 2026
$5.9M
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's DiseaseR01AG073291 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2021 to 2025
$3.2M
Determine the role of atmospheric particulate matter pollutants in contributing to Lewy Body DementiaRF1AG079487 · NIA · JOHNS HOPKINS UNIVERSITY · PI LIU, PENGFEI, MAO, XIAOBO · 2023 to 2023
$2.3M
Heterochronic Blood Exchange Inhibits α?Synucleinopathy through Modulating Plasma Protein's Mediation on Pathological α?Synuclein SpreadingR01AG071820 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2021 to 2025
$2.3M
α-Synuclein strain properties are associated with diagnosis of and progression to Parkinson's disease with dementiaRF1NS125592 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO, ROSENTHAL, LIANA ISA SHAPIRO · 2022 to 2022
$2.1M
Understanding the Mechanism of Pathological alpha-Synuclein TransmissionR01NS107318 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2019 to 2023
$2.0M
Influence of Aging on Pathogenic Alpha-Synuclein Strains and Transmission MechanismK01AG056841 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAO, XIAOBO · 2017 to 2021
$651k
NIAID NIH HHS R01 AI144422NIA NIH HHS K01 AG056841NIA NIH HHS P30 AG066507NIA NIH HHS P50 AG005146NIA NIH HHS R01 AG071820NIA NIH HHS R01 AG073291NIA NIH HHS RF1 AG079487NIA NIH HHS U01 AG033655NIA NIH HHS U19 AG033655NINDS NIH HHS P30 NS050274NINDS NIH HHS R01 NS107318NINDS NIH HHS R21 NS125559NINDS NIH HHS RF1 NS125592
6 · The paper itself

Abstract

The spread of prion-like protein aggregates is believed to be a common driver of pathogenesis in many neurodegenerative diseases. Accumulated tangles of filamentous Tau protein are considered pathogenic lesions of Alzheimer's disease (AD) and related Tauopathies, including progressive supranuclear palsy, and corticobasal degeneration. Tau pathologies in these illnesses exhibits a clear progressive and hierarchical spreading pattern that correlates with disease severity

Indexed as

Lag3PFFprion-likereceptorTau

Identifiers

PMID37293032
PMCPMC10245704
OpenAlexW4377024626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.